Nutriband Inc. (NASDAQ: NTRB) has been added to the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth Indexes as part of the 2025 Russell indexes reconstitution. This inclusion is a significant milestone for the company, reflecting its growing market recognition and the momentum behind its AVERSA pipeline, particularly AVERSA Fentanyl. CEO Gareth Sheridan emphasized the potential peak annual U.S. sales of AVERSA Fentanyl, estimated between $80 million and $200 million, underscoring the product's importance in the pharmaceutical market.
The Russell indexes, maintained by FTSE Russell, serve as a benchmark for approximately $10.6 trillion in assets, making them a critical reference for investment managers and institutions worldwide. Nutriband's addition to these indexes not only enhances its visibility among investors but also underscores the company's potential for growth and innovation in the transdermal pharmaceutical sector. The AVERSA technology, which can be incorporated into any transdermal patch, is designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, addressing a critical need in the healthcare industry.
For more information on Nutriband Inc. and its developments, visit https://www.Nutriband.com. Additional updates and news relating to NTRB can be found in the company’s newsroom at https://ibn.fm/NTRB.
